Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Immunovant, Inc. Director's Dealing 2025

May 6, 2025

31436_dirs_2025-05-05_773fcabe-c372-4eb2-80f1-5525a9d38efb.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immunovant, Inc. (IMVT)
CIK: 0001764013
Period of Report: 2025-05-01

Reporting Person: Girao Tiago (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-05-01 Common Stock A 208388 Acquired 208388 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-05-01 Stock Option (Right to Buy) $15.90 A 293505 Acquired 2035-05-01 Common Stock (293505) Direct

Footnotes

F1: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the total shares on April 21, 2026 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

F2: These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares on April 21, 2026 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.